Artiva Biotherapeutics, Inc. ARTV
Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) is an immunology/inflammation drug developer. Its lead program, AlloNK (AB-101) plus rituximab, is in Phase 2 for Refractory rheumatoid arthritis (lead); also Sjögren’s disease, systemic sclerosis, idiopathic inflammatory myopathies. Its next catalyst on record is AlloNK: Primary efficacy data from registrational Phase 3 trial (H2 2028).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: AlloNK — Primary efficacy data from registrational Phase 3 trial (H2 2028). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| AlloNK + rituximab, planned registrational Phase 3 (approx. 150 patients) | Refractory RA (inadequate response to 2+ b/tsDMARD classes) | cell therapy | Phase 3 |
| AlloNK (AB-101) + rituximab, Phase 2a basket trial | Refractory RA, SjD, IIM, SSc | cell therapy | Phase 2 |
| AlloNK + mAb, investigator-initiated basket trial | B-cell driven autoimmune diseases | cell therapy | Phase 2 |
| AlloNK + rituximab, Phase 1/2 trial | Relapsed/refractory B-cell non-Hodgkin lymphoma (completed July 2025; long-term follow-up discontinued) | cell therapy | Phase 2 |
Recent results and decisions
- Oct 27, 2026discontinued Artiva discontinues AlloNK development after updated longer-term data showed durability of clinical response did not meet threshold required to support continued development, and following two Grade 5 safety events.
Updated clinical response data from patients receiving AlloNK in combination with rituximab continued to demonstrate deep B cell depletion and clinical activity consistent with the Company's previously reported findings. However, longer-term follow-up did not reflect the level of durability of clini
Filing - Oct 27, 2026discontinued Artiva discontinues AlloNK development, halting planned Phase 3 pivotal trial.
Company halting further development of AlloNK® (AB-101), including the planned phase 3 pivotal trial
Filing - Oct 27, 2026clinical hold FDA placed clinical hold on AlloNK Phase 2a study following a fatal neurological event assessed as likely fludarabine-associated neurotoxicity.
Following notification, the FDA asked Artiva to pause enrollment and dosing in the Phase 2a study.
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.